Skip to main content
      RT @synovialjoints: Improving access and education to SLE patients using the Lupus 100 project which uses native languag

      Dr. Antoni Chan synovialjoints

      1 year 4 months ago
      Improving access and education to SLE patients using the Lupus 100 project which uses native language covering 95% of the European population to provide high quality and accurate information for patients by Zoe Karakla-Mitsakou Abst#OP0004 @RheumNow https://t.co/mWRiZt7uGy
      RT @drdavidliew: Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid m

      David Liew drdavidliew

      1 year 4 months ago
      Great patient-driven initiative to get accurate and relevant lupus information to SLE patients. Avoid misinformation and check it out in your language at https://t.co/R2ydvDasFY Congratulations @LupusEurope! #EULAR2023 OP0004 @RheumNow https://t.co/S4sgy5dnro
      RT @AurelieRheumo: Leiden arthritis clinic:
      1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at d

      Aurelie Najm AurelieRheumo

      1 year 4 months ago
      Leiden arthritis clinic: 1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs More marked in ACPA+ pts Is leptin the missing link? 🤓 OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn
      RT @drdavidliew: Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any d

      David Liew drdavidliew

      1 year 4 months ago
      Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE
      RT @Janetbirdope: Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step

      Janet Pope Janetbirdope

      1 year 4 months ago
      Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow https://t.co/Bv1q8IphqF
      RT @NoufAhmedAlham2: Different B cell depleting agents! #Eular2023 https://t.co/GsmdIHgOcl

      Nouf Al hemmadi NoufAhmedAlham2

      1 year 4 months ago
      Different B cell depleting agents! #Eular2023 https://t.co/GsmdIHgOcl
      RT @Janetbirdope: Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine

      Janet Pope Janetbirdope

      1 year 4 months ago
      Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine who will develop #rheumatoidarthritis in Pts with #arthralgia but the real study could be ask #clinician the #probability of RA and do #AI and see comparative accuracy @RheumNow
      RT @drdavidliew: There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we can’t ju

      David Liew drdavidliew

      1 year 4 months ago
      There are lots of reasons why axSpA treatments fail for patients. And as rheumatologists, we can’t just prescribe and walk away - we need to address each in turn, for our patients’ sake #EULAR2023 @RheumNow https://t.co/hzo57BaEXw
      RT @Janetbirdope: #Precision medicine in #SLE #Interferon is not a good predictor of remission as it takes a LONG time t

      Janet Pope Janetbirdope

      1 year 4 months ago
      #Precision medicine in #SLE #Interferon is not a good predictor of remission as it takes a LONG time to normalize in #Lupus @RheumNow @eular_org #EULAR2023 abst#OP https://t.co/JkWnk94bHu
      RheumNow’s expanded coverage of the #EULAR2023 Annual meeting is sponsored in part by Bristol Myers Squibb. All conten

      Dr. John Cush RheumNow

      1 year 4 months ago
      RheumNow’s expanded coverage of the #EULAR2023 Annual meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its Faculty.
      RT @Janetbirdope: EULAR opens their meeting as a leader in #Rheumatology education and &gt;5800 abstracts. A warm welcom

      Janet Pope Janetbirdope

      1 year 4 months ago
      EULAR opens their meeting as a leader in #Rheumatology education and >5800 abstracts. A warm welcome for #EULAR2023 from the president! ⁦@RheumNow⁩ Opening ceremony. Impressive! https://t.co/RLQLQGOA8K
      RT @drdavidliew: When does RA get complicated?

      Many things can burden our patients, making their RA difficult to treat

      David Liew drdavidliew

      1 year 4 months ago
      When does RA get complicated? Many things can burden our patients, making their RA difficult to treat #EULAR2023 @RheumNow https://t.co/FM1UCNbmKr
      RT @Janetbirdope: Researchers@of tomorrow. Winners of EULAR basic and epi and clinical abstract awards - young leaders!

      Janet Pope Janetbirdope

      1 year 4 months ago
      Researchers@of tomorrow. Winners of EULAR basic and epi and clinical abstract awards - young leaders! ⁦@RheumNow⁩ #EULAR2023 ⁦@eular_org⁩ https://t.co/VsV5aQpxjs
      RT @Yuz6Yusof: Delighted to be reporting for @RheumNow LIVE from Milan 🇮🇹 #EULAR2023 alongside my esteemed colleag

      Md Yuzaiful Md Yusof Yuz6Yusof

      1 year 4 months ago
      Delighted to be reporting for @RheumNow LIVE from Milan 🇮🇹 #EULAR2023 alongside my esteemed colleagues @drdavidliew @Janetbirdope @jeffsparks @synovialjoints @AurelieRheumo @bella_mehta 🙌🏻 Do follow us for Congress coverage 😃 https://t.co/tmD4vVWnQk